Peptides have long attracted attention in the scientific community due to their structural simplicity yet vast range of ...

Tesamorelin is a synthetic 44–amino acid analog of growth hormone–releasing hormone (GHRH) that has attracted attention outside the experimental domain for its potential as a research tool. This ...

or on the link below. Differentiated thyroid cancer and breast cancer account for a significant portion of endocrine-related malignancies and predominately affect women. As hormonally-responsive ...

Our evolving understanding of the underlying biology of breast cancer, both early in the disease and as resistance develops with current treatments, continues to advance and enables the development of ...

Stefan Bornstein, MD, PhD, professor, made it clear during a press conference at the 67th Congress of the German Society of Endocrinology (DGE) that there is more than one interaction between them.

Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study. This is an ASCO Meeting Abstract from ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Researchers report links between third-trimester exposure to endocrine disruptors and higher behavioural risk scores in early childhood.